Abstract

OBJECTIVE: We waimed to investigate whether HS can relieve the myocardial fibrosis caused by doxorubicin through Keap1-Nrf2.METHODS: Sprague-Dawley (SD) rats were randomly divided into four groups: normal control group (Control); DOX model group (DOX); HS intervention model group (DOX+HS); HS control group (HS). DOX and DOX+HS group were injected with doxorubicin (3.0 mg/kg/time) intraperitoneally. Both of the Control group and HS groups were given normal saline in equal volume, 2 weeks later, DOX+HS and HS group were controlled with NaHS (56 mol/kg/d) through the abdominal cavity, while the Control and DOX group were injected with normal saline of the same dosage intraperitoneally.RESULTS: Myocardial injury and myocardial cell apoptosis were significantly increased, the HS content in myocardial tissue was remarkably down-regulated, the expression levels of MDA, Keap1, caspase-3, caspase-9, TNF-, IL1, MMPs and TIMP-1 in rat myocardial tissue was significantly up-regulated ( 0.05), and the expression levels of GSH, NQO1, Bcl-2 were down-regulated compared with those of control group. The above results can be reversed by the DOX+HS group. There is no statistically significant difference between the Control group and the HS control group.CONCLUSIONS: These results suggest that HS can improve DOX-induced myocardial fibrosis in rats, and the keap1/Nrf2 signaling pathway, oxidative stress, inflammation, and apoptosis may be involved in the mechanism.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call